TG Therapeutics, Inc.
TGTX
株式のランク
#2357
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
株価
$54.08
時価総額
$8.28B
変化（1日）
-0.83%
変化（1年）
53.55%
国
US
取引 TG Therapeutics, Inc. (TGTX)
カテゴリー
Healthcare
TG Therapeutics, Inc.（TGTX）の発行済株式数
June 2026 時点の発行済株式数 141.77M
TG Therapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 141.77M です。December 2023 の終わりには、同社は 141.96M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
TG Therapeutics, Inc.（TGTX）の発行済株式数の履歴（2000 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 141.77M | -2.44% |
| 2024 | 145.32M | 2.37% |
| 2023 | 141.96M | 4.83% |
| 2022 | 135.41M | 2.41% |
| 2021 | 132.22M | 14.64% |
| 2020 | 115.33M | 30.51% |
| 2019 | 88.37M | 17.10% |
| 2018 | 75.47M | 21.58% |
| 2017 | 62.07M | 26.57% |
| 2016 | 49.04M | 7.44% |
| 2015 | 45.65M | 33.98% |
| 2014 | 34.07M | 34.06% |
| 2013 | 25.41M | 93.80% |
| 2012 | 13.11M | 580.81% |
| 2011 | 1.93M | 4,742.37% |
| 2010 | 39.78K | 58.41% |
| 2009 | 25.11K | 0.00% |
| 2008 | 25.11K | 3.84% |
| 2007 | 24.18K | 13.15% |
| 2006 | 21.37K | 38.05% |
| 2005 | 15.48K | 61.66% |
| 2004 | 9.58K | 20.31% |
| 2003 | 7.96K | 78.92% |
| 2002 | 4.45K | 291.98% |
| 2001 | 1.14K | 160.92% |
| 2000 | 435.00 | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 79.09% |
US
|
|
| 396.00M | 179.33% |
US
|
|
| 478.91M | 237.81% |
AU
|
|
| 62.19M | -56.14% |
NL
|
|
| - | - |
CH
|
